Drug class in one race
No discrete molecular target drugs for Non-Small Cell Lung Cancer
6 tracked No discrete molecular target drugs in the Non-Small Cell Lung Cancer race. The class explanation lives on the No discrete molecular target page; the full indication pipeline across every mechanism is on the Non-Small Cell Lung Cancer page.
3 Phase 22 Phase 1/21 Phase 1
Head-to-head evidence: KB-GDT-01 vs LN-145 · KB707 vs LN-145 · LN-145 vs Olvimulogene nanivacirepvec · LN-145 vs RP1 · LN-145 vs SL-28